Влияние концентрации иматиниба в плазме на достижение молекулярной ремиссии у больных хроническим миелолейкозом
Куцев Сергей Иванович, О. С. Оксенюк, М. В. Вельченко · Kazan medical journal · 2009
Examined was the relationship between the concentration of imatinib in blood plasma and the formation of molecular remission in 49 patients with chronic myeloleukemia during monotherapy with imatinib. Cmin of imatinib in the group of patients with molecular remission was higher than that in the group without molecular remission. Found was a correlation between Cmin of imatinib and the level of BCR-ABL gene expression. At low levels of imatinib in the blood plasma recommended was an increase of the daily dose to achieve a molecular remission.
Cited by 0 works.